Axsome Therapeutics (NASDAQ: AXSM) and Allergan (NYSE: AGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risks, profitability, institutional ownership, income, analyst recommendations and valuation.
Risk and volatility
Axsome Therapeutics has a beta of -0.15, which suggests that the share price is 115% less volatile than the S & P 500. In comparison Allergan has a beta of 1.21, which suggests that the share price is 21% volatile than the S & P 500.
Allergan pays an annual dividend of $ 2.88 per share and has a dividend yield of 1.5%. Axsome Therapeutics does not pay a dividend. Allergan pays 17.6% of its income in the form of a dividend.
Appreciation and profit
This table compares the operating income, earnings per share (EPS) and valuation of Axsome Therapeutics and Allergan.
|Gross income||Price / sales ratio||Net income||Profit per share||Price / profit ratio|
|Axsome Therapeutics||N / A||N / A||– $ 28.94 million||($ 1.24)||-2.78|
|Allergan||$ 15.94 billion||4.06||– $ 4.13 billion||$ 16.35||11.65|
Axsome Therapeutics has higher revenues, but lower revenues than Allergan. Axsome Therapeutics is trading at a lower price-earnings ratio than Allergan, indicating that it is currently the more affordable of the two stocks.
This table compares the net margins of Axsome Therapeutics and Allergan, return on equity and return on assets.
|Net margins||Return on equity||Return on assets|
|Axsome Therapeutics||N / A||-198.09%||-89.32%|
Institutional & Insider Ownership
15.6% of Axsome Therapeutics shares are held by institutional investors. By comparison, 77.3% of the Allergan shares are held by institutional investors. 34.3% of Axsome Therapeutics shares are owned by insiders. In comparison, 0.4% of the Allergan shares are owned by insiders. Strong institutional ownership is an indication that donations, large money managers and hedge funds are of the opinion that a company will perform better than the market in the long term.
Recommendations from analysts
This is a specification of the current recommendations and price targets for Axsome Therapeutics and Allergan, as reported by MarketBeat.
|Sales reviews||Keep ratings||Buy ratings||Strong sales figures||Review score|
Axsome Therapeutics currently has a consensus target of $ 13.00, suggesting a potential benefit of 276.81%. Allergan has a consensus target of $ 214.85, suggesting a potential benefit of 12.80%. Given Axsome Therapeutics a stronger consensus assessment and a higher possible benefit, analysts clearly believe that Axsome Therapeutics is more beneficial than Allergan.
Allergan beats Axsome Therapeutics on 8 of the 14 factors that are compared between the two stocks.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc., a clinical biopharmaceutical company, is developing new therapies for diseases of the central nervous system (CNS). The candidate product portfolio includes AXS-05, AXS-09, AXS-02, AXS-07 and AXS-06. AXS-05 is in the Phase III clinical trial with treatment-resistant depression and agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical study in osteoarthritis of the knee associated with bone marrow lesions under a special protocol assessment and in chronic low back pain associated with Modical changes. AXS-07 is in Phase I clinical study for the acute treatment of migraine. AXS-06 is also in Phase I clinical study for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of non-steroidal anti-inflammatory drug-associated ulcers. AXS-09 is a new, oral drug combination of esbupropion and dextromethorphan, which is part of a Phase I clinical study. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a phase II study on smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Allergan Company profile
Allergan plc, a pharmaceutical company, develops, manufactures and markets pharmaceutical products, appliances, biological, surgical and regenerative medicines worldwide. It works through American specialized therapies, American general medicine and international segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. It also offers breast implants and tissue enlargers; RM-131 (relamorelin), a peptide-ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; therapeutics for small molecules that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has an agreement for collaboration, option and license with Lyndra, Inc .; strategic alliance and option agreement with Editas Medicine, Inc .; and licensing agreements with Assembly Biosciences, Inc. MedImmune and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Receive news and ratings for Axsome Therapeutics Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Axsome Therapeutics and related companies with the FREE daily email newsletter from MarketBeat.com.